Linezolid is indicated in adult for treatment of the following infections caused by susceptible strains of the designated microorganisms:
– Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia.
– Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains)
– Complicated skin and skin structure infections, caused by Staphylococcus aureus (methicillin-susceptible and ­resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae.
– Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogeness
– Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only).

This is only the preview. Please check here for the full indication.

Anatomical Therapeutic Chemical: J
Dosage form: Film coated tablet
Packaging: 10's x 2
Therapeutic area: Active pharmaceutical ingredient: